Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)Piero Barbanti, Ilaria Cetta, Paola Di Fiore et al.|The Journal of Headache and Pain|2022Cited by 105
Fremanezumab in the Prevention of High-Frequency Episodic and Chronic Migraine: A 12-Week, Multicenter, Real-Life, Cohort Study (The FRIEND Study).Piero Barbanti, Fabrizio Vernieri, Gabriella Egeo et al.|Research Square|2021Cited by 6
Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)Piero Barbanti, Gabriella Egeo, Cinzia Aurilia et al.|The Journal of Headache and Pain|2022Cited by 5
Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)Piero Barbanti, Gabriella Egeo, Cinzia Aurilia et al.|The Journal of Headache and Pain|2022Cited by 1